Rocket Pharmaceuticals, Inc.
NASDAQ:RCKTBiotechnology
+$0.06 today
- Market cap
- $235.60M
- Beta
- 0.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$1.87
Volume 2.49M
Average 3.15M
RCKT Interest Expense
Cost of servicing the company's debt during the period.
Rocket Pharmaceuticals, Inc.NASDAQ: RCKT
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense grows, but more slowly than its trailing trend
Q1 FY2026 interest expense of $473K rose 0.2% year over year, behind the +150.6% change in trailing-twelve-month interest expense. Sequentially, it fell 85.7% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Interest expense increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +0.2% toward the trailing-twelve-month pace of +150.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 1.89M USD
- Year-over-year change
- +0.3%
- 4-year CAGR
- -24.7%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.89M | +0.3% |
| FY2024 | 2024-12-31 | 1.89M | +0.6% |
| FY2023 | 2023-12-31 | 1.88M | -1.8% |
| FY2022 | 2022-12-31 | 1.91M | -67.6% |
| FY2021 | 2021-12-31 | 5.89M | — |
Interest Expense vs competitors
How RCKT compares with its peers on the latest reported figures
- RCKT's LTM Mar 2026 interest expense of $4.73M is the 3rd highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +150.6% is the 3rd highest of 5, against a peer median of +251.1%.
- Over three fiscal years its annual growth of -0.3% compares with a peer median of +76.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $44.43M | +26345.5% | +60.4% | 48.0% | |
| LTM Mar 2026 | $7.57M | +21.5% | +92.2% | — | |
| LTM Mar 2026 | $4.73M | +150.6% | -0.3% | — | |
| LTM Mar 2026 | $656.17K | +480.7% | — | — | |
| LTM Mar 2026 | $60K | -80.8% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$206.5K | — | — | — |
| Peer median (excluding RCKT) | $0 | +251.1% | +76.3% | 24.0% | |
Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.03M |
| Gross Profit | 0 | 0 | 0 | 0 | (11.03M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 125.48M | 165.57M | 186.34M | 171.24M | 142.02M |
| Selling, General & Admin | 41.77M | 58.77M | 73.32M | 101.96M | 86.5M |
| Operating Expenses | 167.25M | 224.34M | 259.66M | 273.21M | 217.49M |
| Depreciation & Amortization | 5.37M | 6.27M | 7.1M | 9.38M | 11.03M |
| EBITDA | (157.81M) | (213.69M) | (236.62M) | (247.49M) | (210.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (167.25M) | (224.34M) | (259.66M) | (273.21M) | (228.52M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3.07M | 3.89M | 15.94M | 18.22M | 10.62M |
| Interest Expense | 5.89M | 1.91M | 1.88M | 1.89M | 1.89M |
| Other Income / Expenses | (1.82M) | 2.48M | 14.06M | 14.46M | 5.39M |
| Income Before Tax | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.68) | (3.26) | (2.92) | (2.73) | (2.01) |
| EPS (Diluted) | (2.68) | (3.26) | (2.92) | (2.73) | (2.01) |
| Weighted Avg Shares | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M |
| Weighted Avg Shares (Diluted) | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M |
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
Intrinsic Alpha fair value
Locked
Current Price
$2.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.